ONCOmmunity

Circulating CD95-ligand as a potential prognostic marker for recurrence in patients with synchronous colorectal liver metastases

By: Hoogwater FJ, Snoeren N, Nijkamp MW, Gunning AC, VAN Houdt WJ, DE Bruijn MT, Voest EE, VAN Hillegersberg R, Kranenburg O, Rinkes IH.

Department of Surgery, G.04.228, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
Anticancer Res. 2011 Dec; 31(12):4507-12.

Abstract

Aim

To assess whether circulating soluble CD95 ligand (sCD95L) levels are associated with recurrence-free survival (RFS) in patients with synchronous colorectal liver metastases.

Patients and Methods

Blood samples were obtained from 62 patients with synchronous colorectal liver metastases before and after liver surgery. Serum sCD95L levels were determined using enzyme-linked immunosorbent assay (ELISA). Cox regression analysis was performed to determine the correlation between sCD95L levels and RFS and overall survival (OS).

Results

Median follow-up was 33 months. High pre-operative sCD95L levels were associated with poor RFS and OS in univariable (p=0.019 and p=0.020) and multivariable analyses (p=0.020 and p=0.003).

Conclusion

Preoperatives CD95L is a potential prognostic factor for RFS and OS of patients undergoing surgery for synchronous colorectal liver metastases. Low preoperatives CD95L levels may help identify a subgroup of patients with synchronous liver metastases that are likely to benefit from liver surgery.

PMID: 22199323 [PubMed - indexed for MEDLINE] Source: National Library of Medicine.